Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 26, 2015 1:00 PM ET


Company Overview of Oryzon Genomics S.A.

Company Overview

Oryzon Genomics S.A., a biopharmaceutical company, develops and commercializes biomarkers identified through genomics and proteomics in the fields of diagnostics, personalized medicine, and therapy. Its products pipeline comprises GynEC-DX, a diagnostic test for endometrial cancer; ColoBRAF, a genetic test that verifies the presence of the BRAF-V600E mutation in MSI-H tumors; and Cxbladder, a non-invasive bladder cancer diagnostic test. The company also develops small molecules and monoclonal antibodies for various indications, including leukemia and other cancers, PD/AD and other dementias, Huntington, viral infections, squamous cell cancer, prostate cancer, and endometrial cancer. In addit...

Sant Ferran 74

Cornellà de Llobregat

Barcelona,  08940


Founded in 2000


34 93 515 13 13


34 93 377 40 28

Key Executives for Oryzon Genomics S.A.

Co-Founder, Chairman, Chief Executive Officer, President and Member of Financial Advisory Board
Co-Founder, Scientific Director and Director
Global Chief Financial Officer, Executive Vice President, Director and Chairman of Audit Committee
Age: 59
Chief Intellectual Property Officer
Investor Relations Director
Compensation as of Fiscal Year 2015.

Oryzon Genomics S.A. Key Developments

Oryzon Genomics Appoints Board of Directors

Oryzon Genomics announced the appointment of Mr. Antonio Fornieles, Ms. Isabel Aguilera and Mr. Ramon Adell as independent directors to the company's Board of Directors, effective November 3, 2015. The addition of three independent directors, approved by shareholders, strengthens the board of Oryzon, as the company prepares to go public on the Spanish Continuous Market in Madrid. Mr. Antonio Fornieles, Ms. Isabel Aguilera and Mr. Ramon Adell have substantial expertise and will be valuable contributors to Oryzon's mission and anticipated needs. Mr. Antonio Fornieles will act as Lead Director, Ms. Isabel Aguilera will act as Chairman of the Remuneration and Nomination Committee, and Mr. Ramon Adell will be chairing the Audit and Compliance Committee. Mr. Antonio Fornieles brings to Oryzon over 30 years of audit experience. Mr. Fornieles has been Second Vice Chairman at Abengoa SA since January 2015 and also serves as its lead director. Previously as Global Chief Operating Officer at KPMG. Ms. Isabel Aguilerais is currently a Non-Executive Director and adviser to various companies, such as Indra, Banco BMN, AEGON Spain and EGASA. Mr. Ramon Adell serves as Professor of Financial Economics and Accounting at the University of Barcelona.

Oryzon Genomics S.A. Presents at BIO-Europe 2015, Nov-04-2015 09:45 AM

Oryzon Genomics S.A. Presents at BIO-Europe 2015, Nov-04-2015 09:45 AM. Venue: Munich, Germany.

ORYZON Presents at Rodman & Renshaw 17th Annual Global Investment Conference, Sep-08-2015

ORYZON Presents at Rodman & Renshaw 17th Annual Global Investment Conference, Sep-08-2015 . Venue: The St. Regis Hotel, Two East 55th Street, New York, NY 10022, United States.

Similar Private Companies By Industry

Company Name Region
Fénix Biotech S.L. Europe
Draconis Pharma SL Europe
Espanola de I+D Europe
Biotechnology Consulting, S.L. Europe
Instituto Grifols, S.A. Europe

Recent Private Companies Transactions

Private Placement
August 7, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Oryzon Genomics S.A., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at